Latus Bio Secures $42 Million to Advance Gene‑Therapy Trials for Huntington’s Disease
Stat News reports that biotech startup Latus Bio has raised $42 million to launch its first clinical trials targeting Huntington’s disease. The funding will also support a parallel trial for CLN2 Batten disease, aiming to overcome setbacks experienced by a more advanced competitor.
რეკლამა: Article Inline